Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C. Renneville A, et al. Among authors: hayette s. Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13. Leukemia. 2012. PMID: 22289988
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC, Escoffre M, Huguet F, Réa D, Delannoy A, Cahn JY, Vernant JP, Ifrah N, Dombret H, Thomas X. Tanguy-Schmidt A, et al. Among authors: hayette s. Biol Blood Marrow Transplant. 2013 Jan;19(1):150-5. doi: 10.1016/j.bbmt.2012.08.021. Epub 2012 Sep 6. Biol Blood Marrow Transplant. 2013. PMID: 22960387 Free article. Clinical Trial.
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Lambert J, Lambert J, Nibourel O, Pautas C, Hayette S, Cayuela JM, Terré C, Rousselot P, Dombret H, Chevret S, Preudhomme C, Castaigne S, Renneville A. Lambert J, et al. Among authors: hayette s. Oncotarget. 2014 Aug 15;5(15):6280-8. doi: 10.18632/oncotarget.2196. Oncotarget. 2014. PMID: 25026287 Free PMC article. Clinical Trial.
Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.
Huet S, Cony-Makhoul P, Heiblig M, Tigaud I, Gazzo S, Belhabri A, Souche D, Michallet M, Magaud JP, Hayette S, Nicolini F. Huet S, et al. Among authors: hayette s. PLoS One. 2014 Sep 9;9(9):e106250. doi: 10.1371/journal.pone.0106250. eCollection 2014. PLoS One. 2014. PMID: 25203717 Free PMC article.
The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.
Chien WW, Catallo R, Chebel A, Baranger L, Thomas X, Béné MC, Gerland LM, Schmidt A, Beldjord K, Klein N, Escoffre-Barbe M, Leguay T, Huguet F, Larosa F, Hayette S, Plesa A, Ifrah N, Dombret H, Salles G, Chassevent A, Ffrench M. Chien WW, et al. Among authors: hayette s. Leuk Res. 2015 Apr;39(4):453-61. doi: 10.1016/j.leukres.2015.01.008. Epub 2015 Jan 25. Leuk Res. 2015. PMID: 25675863
118 results